BRIASETA

This brand name is authorized in Estonia, Ireland.

Active ingredients

The drug BRIASETA contains one active pharmaceutical ingredient (API):

1	Ambrisentan UNII HW6NV07QEC - AMBRISENTAN
	Ambrisentan is an orally active, propanoic acid-class, ERA selective for the endothelin A (ETA) receptor. Endothelin plays a significant role in the pathophysiology of PAH.
	Read more about Ambrisentan

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BRIASETA Film-coated tablet	MPI, EU: SmPC	Health Products Regulatory Authority (IE)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C02KX02	Ambrisentan	C Cardiovascular system → C02 Antihypertensives → C02K Other antihypertensives → C02KX Antihypertensives for pulmonary arterial hypertension
Discover more medicines within C02KX02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1827851, 1827862, 1827873, 1827884, 1827895, 1827907, 1827918, 1827929